p53 in malignant and benign liver lesions

Area of Science:

• Oncology
• Molecular Biology
• Hepatology

Background:

• The p53 tumor suppressor protein plays a critical role in cellular response to DNA damage.
• Alterations in p53 are common in various cancers, including hepatocellular carcinoma (HCC).
• Understanding p53 expression patterns in different liver lesions is crucial for diagnosis and understanding tumorigenesis.

Purpose of the Study:

• To investigate the expression of p53 protein in benign and malignant human epithelial liver lesions.
• To determine the prevalence of p53 overexpression in hepatocellular carcinoma (HCC) in a Hungarian cohort.
• To explore potential associations between p53 expression and etiological factors in HCC.

Main Methods:

• Immunohistochemical analysis was employed to detect p53 protein expression.
• The study included 46 patients with various liver lesions from Hungary.
• Specific focus was placed on hepatocellular carcinomas, hepatoblastomas, focal nodular hyperplasias, and hepatocellular adenomas.

Main Results:

• Positive p53 immunostaining was observed in the nuclei of tumor cells in 7 out of 16 (44%) hepatocellular carcinoma (HCC) cases.
• p53 expression was also detected in one hepatoblastoma case.
• No p53 immunostaining was found in focal nodular hyperplasias or hepatocellular adenomas.

Conclusions:

• The relatively high incidence of p53 detection in Hungarian HCC cases suggests that factors beyond aflatoxin exposure contribute to p53 accumulation.
• These findings indicate that non-aflatoxin-related mechanisms are significant in the pathogenesis of HCC in this population.
• Further research is warranted to identify the specific non-aflatoxin factors responsible for p53 overexpression in HCC.